Evidence from preclinical studies indicates that purpurin exerts beneficial effects in Alzheimer’s disease, depression, ischemic stroke, and age-related cognitive decline, primarily through anti-tau aggregation, cholinesterase inhibition, serotonergic modulation, antioxidant activity, and anti-inflammatory mechanisms. This evidence concerns the gene BCHE and major depressive disorder.